LifeSciences BC > News > Industry News > 2014 > Tekmira reorganizes management team

Print Friendly

B.C. Industry News

Tekmira reorganizes management team

January 7, 2014

Biotechnology Focus

Vancouver based Tekmira Pharmaceuticals Corporation has announced a reorganization of its leadership team. As part of these changes, effective January 6, 2014, Dr. Michael Abrams will join the company as executive vice president and chief discovery officer, and Dr. Ian MacLachlan will head a newly formed group focused on medical countermeasures as executive vice president and chief technical Officer.

“We are pleased to announce Ian MacLachlan’s appointment as chief technical officer, with a particular focus on developing medical countermeasures. Under Ian’s stewardship, our TKM-Ebola program continues to advance under a contract with U.S. Department of Defense valued at approximately $140 million. By leveraging his extensive knowledge and applying our most recent technology advances, Ian will lead the expansion of this part of our pipeline, seeded with initiatives such as our TKM-Marburg program, to create further shareholder value,” said Dr. Mark  Murray, Tekmira’s president and CEO.

Murray added that the addition of Mike Abrams underscores the importance of the company’s drug discovery efforts in support of a broader pipeline of RNAi-based products.

“Mike is an accomplished drug developer with extensive experience from leadership roles within the biotech and pharmaceutical industry that have led to successfully commercialized therapeutics,” stated Dr. Murray.

Concurrent with Dr. Abrams’ appointment as chief discovery officer, he will resign his position as an independent director on Tekmira’s board. Prior to joining Tekmira, Dr. Abrams was chief innovation officer and VP, Research and Development at CDRD Ventures Inc. Previously, he was president and CEO of Inimex, and the founding CEO of AnorMED, Inc. AnorMED discovered and developed Mozobil, a drug for improving stem cell mobilization for patients undergoing stem cell transplantation. Mozobil was approved by the FDA in 2008 and AnorMED was acquired by Genzyme Corp. in 2006 for $580M.